Posted On: 11/08/2013 3:50:15 PM
Post# of 102855
$GILD Recent News
Selling in growth-stock leaders continues
11:23 a.m. Oct. 31, 2013
- The Trading Deck
LinkedIn, Yelp decline; Baidu rallies after hours
5:14 p.m. Oct. 29, 2013
- Wallace Witkowski
Gilead profit up 17% as HIV drugs top sales growth
4:07 p.m. Oct. 29, 2013
- MarketWatch.com
Gilead shares rise 1% in late trading
3:59 p.m. Oct. 29, 2013
- Laura Mandaro
Earnings season focus shifts to revenue, capex
8:53 a.m. Oct. 27, 2013
- Wallace Witkowski
Healthcare stocks fall from first place in race for year's best-performing sector
2:32 p.m. Oct. 24, 2013
- blogs.marketwatch.com
In focus: Overbought conditions abound
7:21 p.m. Oct. 23, 2013
- Lawrence G. McMillan
Best Buy tops S&P 500; Netflix snaps losing streak
3:21 p.m. Oct. 10, 2013
- Sue Chang
Best Buy, Gilead Sciences lead S&P 500 gainers
3:05 p.m. Oct. 10, 2013
- Polya Lesova
Gilead, Acura stand out on up day for stocks, Quest tumbles
10:27 a.m. Oct. 10, 2013
- Russ Britt
Gilead ends leukemia study after positive results
4:10 p.m. Oct. 9, 2013
- MarketWatch.com
Citrix, Ruby Tuesday shares fall after hours
4:06 p.m. Oct. 9, 2013
- Wallace Witkowski
10 popular health-care stocks among hedge funds
11:34 a.m. Sept. 4, 2013
- Insider Monkey
Charting a market divergence
10:21 a.m. Aug. 22, 2013
- Michael Ashbaugh
Earnings help McKesson, hospitals; FDA ruling hits Vertex, aids Gilead
9:52 a.m. July 26, 2013
- Russ Britt
S&P 500 up another 5% in 2013: J.P. Morgan's Thomas Lee
8:36 a.m. July 26, 2013
- blogs.marketwatch.com
Gilead soars on rival Vertex's drug-ruling misfortune
4:47 p.m. July 25, 2013
- Russ Britt
Updates, advisories and surprises
4:31 p.m. July 25, 2013
- MarketWatch
Gilead profit up 8.6% on sales growth of HIV drugs
3:37 p.m. July 25, 2013
- MarketWatch.com
Gilead profit rises, sales beat forecast
3:19 p.m. July 25, 2013
- Russ Britt
Gilead Vs. Challengers In The Hepatitis C Race
7:00 a.m. Nov. 7, 2013
- Seeking Alpha
Roche Pacing the Field in the Biotech Race
6:00 a.m. Nov. 6, 2013
- TheStreet.com
U.S. Launch of Actelion's Opsumit - Analyst Blog
4:30 p.m. Nov. 5, 2013
- Zacks.com
Ligand Pharmaceuticals On Pace For Annual Profit
4:25 p.m. Nov. 5, 2013
- Investors Business Daily
Analysts: Gilead Likely to Lead HCV Treatment and 3 More Research Notes to Read
11:25 a.m. Nov. 5, 2013
- Wall St. Cheat Sheet
Gilead Sciences Inc Continues With Buy Recommendation
9:00 a.m. Nov. 5, 2013
- TheStreet.com
UBS Adds Six Top Alpha Preference List Stocks to Buy for 2014
7:34 a.m. Nov. 5, 2013
- 247WallSt.com
Stock Splits Rekindle a Polarizing Debate
8:44 p.m. Nov. 4, 2013
- WSJ.com
Top-Performing Mutual Funds Like Facebook
5:01 p.m. Nov. 4, 2013
- Investors Business Daily
Bristol-Myers Seeks Japanese Approval - Analyst Blog
2:30 p.m. Nov. 4, 2013
- Zacks.com
Protect Your Investments Against a Bubble, Know What Makes a Bubble
10:28 a.m. Nov. 4, 2013
- TheStreet.com
Benzinga's Top #PreMarket Losers
7:37 a.m. Nov. 4, 2013
- benzinga.com
Invest In Gilead Sciences For Long-Term Hepatitis C Franchise
2:13 a.m. Nov. 4, 2013
- Seeking Alpha
Gilead Announces Positive Phase 3 HCV Treatment Results in Patients Co-Infected With HIV
4:15 p.m. Nov. 2, 2013
- benzinga.com
Gilead Announces Promising Phase 2 HCV Treatment Results in Liver Transplant Patients
4:12 p.m. Nov. 2, 2013
- benzinga.com
Why Idenix Could Rise Even Higher, and Challenge Gilead and Vertex
6:40 a.m. Nov. 2, 2013
- 247WallSt.com
Jim Cramer's 6 Stocks in 60 Seconds: VRTX GTLS YELP AVD Q GRPN (Update 1)
5:20 p.m. Nov. 1, 2013
- TheStreet.com
Argus' Market Digest Summary
9:47 a.m. Nov. 1, 2013
- benzinga.com
Top Analyst Upgrades and Downgrades: Facebook, Netflix, PetSmart, Valero and More
7:54 a.m. Nov. 1, 2013
- 247WallSt.com
Bull of the Day: Pharmacyclics (PCYC) - Bull of the Day
4:15 a.m. Oct. 31, 2013
- Zacks.com
S.F. Voters Repudiate Gilead, Other Pharma's Greed with Prop. D Victory
7:47 p.m. Nov. 7, 2013
- BusinessWire
Gilead to Present Data on Oncology Pipeline at American Society of Hematology Annual Meeting
9:00 a.m. Nov. 7, 2013
- BusinessWire
Clinical Trial Data, New Publications, Promotions, Financial Results and FDA Acknowledgements - Research Report on Gilead, Amgen, ACADIA Pharmaceuticals, ViroPharma, and MannKind
8:00 a.m. Nov. 6, 2013
- PR Newswire
Under AAAResearchReports.com Microscope: Gilead Sciences Inc., NPS Pharma Inc., Halozyme Therapeutics Inc., and InterMune Inc.
11:14 a.m. Nov. 4, 2013
- PR Newswire
Quarterly Financial Reports, Clinical Study Results, and R&D Events for the Investment Community - Research Report on Gilead Sciences, Clovis, Theravance, Charles River, and Acorda
8:00 a.m. Nov. 4, 2013
- PR Newswire
Gilead Announces New Sustained Viral Response Data for Sofosbuvir-Based Regimens in Genotype 3-Infected Hepatitis C Patients
9:01 a.m. Nov. 2, 2013
- BusinessWire
Gilead Announces Phase 3 Results for an All-Oral, Sofosbuvir-Based Regimen for the Treatment of Hepatitis C in Patients Co-Infected With HIV
9:01 a.m. Nov. 2, 2013
- BusinessWire
Gilead Announces Phase 2 Results for Sofosbuvir-Based Regimens in Hepatitis C Patients Before and After Liver Transplantation
9:01 a.m. Nov. 2, 2013
- BusinessWire
Dun & Bradstreet CEO Sara Mathew Named Top S&P 500 Wealth Creator in 2013
8:30 a.m. Oct. 31, 2013
- PR Newswire
Sector Leaders Briefing & Capital Raise News: Muscle Warfare, Baidu, Herblife, Gilead Sciences and ARIAD
9:08 a.m. Oct. 30, 2013
- PR Newswire
Gilead Sciences Announces Third Quarter 2013 Financial Results
4:02 p.m. Oct. 29, 2013
- BusinessWire
Critical Alerts For Gilead Sciences, Trina Solar, T Rowe Price, Suncor Energy, and Morgan Stanley Released By InvestorsObserver
9:31 a.m. Oct. 29, 2013
- PR Newswire
The Non-Hodgkin's Lymphoma Drug Market Will Nearly Double to More Than $10 Billion by 2022
9:00 a.m. Oct. 28, 2013
- PR Newswire
FDA Advisory Committee Supports Approval of Gilead's Sofosbuvir for Chronic Hepatitis C Infection
4:43 p.m. Oct. 25, 2013
- BusinessWire
Gilead Sciences to Release Third Quarter 2013 Financial Results on Tuesday, October 29, 2013
5:00 p.m. Oct. 22, 2013
- BusinessWire
Stock Price Movements, Clinical Study Results, and New Appointments - Research Report on Pfizer, Gilead Sciences, Amgen, Celgene, and Insys Therapeutics
8:00 a.m. Oct. 22, 2013
- PR Newswire
Innovative Biotechs Making Strides In Healthcare Sector: Alliqua, MiMedx, Organovo, Anacor Pharmaceuticals, Pfizer
9:05 a.m. Oct. 21, 2013
- PR Newswire
Insider Trading Tips for Google, Rite Aid, American Express, Advanced Micro Devices, J.C. Penney, and Ariad Pharmaceuticals
8:55 a.m. Oct. 21, 2013
- PR Newswire
Gilead's Single Tablet HIV Regimen Stribild(R) Demonstrates Durable Viral Suppression Through Three Years of Therapy
3:10 a.m. Oct. 16, 2013
- BusinessWire
GlobeImmune Announces Milestone Payment for Initiation of Phase 2 Clinical Trial for GS-4774 (Formerly GI-13020) in Patients with Chronic Hepatitis B Virus Infection
7:00 a.m. Oct. 15, 2013
- Thomson Reuters ONE
Selling in growth-stock leaders continues
11:23 a.m. Oct. 31, 2013
- The Trading Deck
LinkedIn, Yelp decline; Baidu rallies after hours
5:14 p.m. Oct. 29, 2013
- Wallace Witkowski
Gilead profit up 17% as HIV drugs top sales growth
4:07 p.m. Oct. 29, 2013
- MarketWatch.com
Gilead shares rise 1% in late trading
3:59 p.m. Oct. 29, 2013
- Laura Mandaro
Earnings season focus shifts to revenue, capex
8:53 a.m. Oct. 27, 2013
- Wallace Witkowski
Healthcare stocks fall from first place in race for year's best-performing sector
2:32 p.m. Oct. 24, 2013
- blogs.marketwatch.com
In focus: Overbought conditions abound
7:21 p.m. Oct. 23, 2013
- Lawrence G. McMillan
Best Buy tops S&P 500; Netflix snaps losing streak
3:21 p.m. Oct. 10, 2013
- Sue Chang
Best Buy, Gilead Sciences lead S&P 500 gainers
3:05 p.m. Oct. 10, 2013
- Polya Lesova
Gilead, Acura stand out on up day for stocks, Quest tumbles
10:27 a.m. Oct. 10, 2013
- Russ Britt
Gilead ends leukemia study after positive results
4:10 p.m. Oct. 9, 2013
- MarketWatch.com
Citrix, Ruby Tuesday shares fall after hours
4:06 p.m. Oct. 9, 2013
- Wallace Witkowski
10 popular health-care stocks among hedge funds
11:34 a.m. Sept. 4, 2013
- Insider Monkey
Charting a market divergence
10:21 a.m. Aug. 22, 2013
- Michael Ashbaugh
Earnings help McKesson, hospitals; FDA ruling hits Vertex, aids Gilead
9:52 a.m. July 26, 2013
- Russ Britt
S&P 500 up another 5% in 2013: J.P. Morgan's Thomas Lee
8:36 a.m. July 26, 2013
- blogs.marketwatch.com
Gilead soars on rival Vertex's drug-ruling misfortune
4:47 p.m. July 25, 2013
- Russ Britt
Updates, advisories and surprises
4:31 p.m. July 25, 2013
- MarketWatch
Gilead profit up 8.6% on sales growth of HIV drugs
3:37 p.m. July 25, 2013
- MarketWatch.com
Gilead profit rises, sales beat forecast
3:19 p.m. July 25, 2013
- Russ Britt
Gilead Vs. Challengers In The Hepatitis C Race
7:00 a.m. Nov. 7, 2013
- Seeking Alpha
Roche Pacing the Field in the Biotech Race
6:00 a.m. Nov. 6, 2013
- TheStreet.com
U.S. Launch of Actelion's Opsumit - Analyst Blog
4:30 p.m. Nov. 5, 2013
- Zacks.com
Ligand Pharmaceuticals On Pace For Annual Profit
4:25 p.m. Nov. 5, 2013
- Investors Business Daily
Analysts: Gilead Likely to Lead HCV Treatment and 3 More Research Notes to Read
11:25 a.m. Nov. 5, 2013
- Wall St. Cheat Sheet
Gilead Sciences Inc Continues With Buy Recommendation
9:00 a.m. Nov. 5, 2013
- TheStreet.com
UBS Adds Six Top Alpha Preference List Stocks to Buy for 2014
7:34 a.m. Nov. 5, 2013
- 247WallSt.com
Stock Splits Rekindle a Polarizing Debate
8:44 p.m. Nov. 4, 2013
- WSJ.com
Top-Performing Mutual Funds Like Facebook
5:01 p.m. Nov. 4, 2013
- Investors Business Daily
Bristol-Myers Seeks Japanese Approval - Analyst Blog
2:30 p.m. Nov. 4, 2013
- Zacks.com
Protect Your Investments Against a Bubble, Know What Makes a Bubble
10:28 a.m. Nov. 4, 2013
- TheStreet.com
Benzinga's Top #PreMarket Losers
7:37 a.m. Nov. 4, 2013
- benzinga.com
Invest In Gilead Sciences For Long-Term Hepatitis C Franchise
2:13 a.m. Nov. 4, 2013
- Seeking Alpha
Gilead Announces Positive Phase 3 HCV Treatment Results in Patients Co-Infected With HIV
4:15 p.m. Nov. 2, 2013
- benzinga.com
Gilead Announces Promising Phase 2 HCV Treatment Results in Liver Transplant Patients
4:12 p.m. Nov. 2, 2013
- benzinga.com
Why Idenix Could Rise Even Higher, and Challenge Gilead and Vertex
6:40 a.m. Nov. 2, 2013
- 247WallSt.com
Jim Cramer's 6 Stocks in 60 Seconds: VRTX GTLS YELP AVD Q GRPN (Update 1)
5:20 p.m. Nov. 1, 2013
- TheStreet.com
Argus' Market Digest Summary
9:47 a.m. Nov. 1, 2013
- benzinga.com
Top Analyst Upgrades and Downgrades: Facebook, Netflix, PetSmart, Valero and More
7:54 a.m. Nov. 1, 2013
- 247WallSt.com
Bull of the Day: Pharmacyclics (PCYC) - Bull of the Day
4:15 a.m. Oct. 31, 2013
- Zacks.com
S.F. Voters Repudiate Gilead, Other Pharma's Greed with Prop. D Victory
7:47 p.m. Nov. 7, 2013
- BusinessWire
Gilead to Present Data on Oncology Pipeline at American Society of Hematology Annual Meeting
9:00 a.m. Nov. 7, 2013
- BusinessWire
Clinical Trial Data, New Publications, Promotions, Financial Results and FDA Acknowledgements - Research Report on Gilead, Amgen, ACADIA Pharmaceuticals, ViroPharma, and MannKind
8:00 a.m. Nov. 6, 2013
- PR Newswire
Under AAAResearchReports.com Microscope: Gilead Sciences Inc., NPS Pharma Inc., Halozyme Therapeutics Inc., and InterMune Inc.
11:14 a.m. Nov. 4, 2013
- PR Newswire
Quarterly Financial Reports, Clinical Study Results, and R&D Events for the Investment Community - Research Report on Gilead Sciences, Clovis, Theravance, Charles River, and Acorda
8:00 a.m. Nov. 4, 2013
- PR Newswire
Gilead Announces New Sustained Viral Response Data for Sofosbuvir-Based Regimens in Genotype 3-Infected Hepatitis C Patients
9:01 a.m. Nov. 2, 2013
- BusinessWire
Gilead Announces Phase 3 Results for an All-Oral, Sofosbuvir-Based Regimen for the Treatment of Hepatitis C in Patients Co-Infected With HIV
9:01 a.m. Nov. 2, 2013
- BusinessWire
Gilead Announces Phase 2 Results for Sofosbuvir-Based Regimens in Hepatitis C Patients Before and After Liver Transplantation
9:01 a.m. Nov. 2, 2013
- BusinessWire
Dun & Bradstreet CEO Sara Mathew Named Top S&P 500 Wealth Creator in 2013
8:30 a.m. Oct. 31, 2013
- PR Newswire
Sector Leaders Briefing & Capital Raise News: Muscle Warfare, Baidu, Herblife, Gilead Sciences and ARIAD
9:08 a.m. Oct. 30, 2013
- PR Newswire
Gilead Sciences Announces Third Quarter 2013 Financial Results
4:02 p.m. Oct. 29, 2013
- BusinessWire
Critical Alerts For Gilead Sciences, Trina Solar, T Rowe Price, Suncor Energy, and Morgan Stanley Released By InvestorsObserver
9:31 a.m. Oct. 29, 2013
- PR Newswire
The Non-Hodgkin's Lymphoma Drug Market Will Nearly Double to More Than $10 Billion by 2022
9:00 a.m. Oct. 28, 2013
- PR Newswire
FDA Advisory Committee Supports Approval of Gilead's Sofosbuvir for Chronic Hepatitis C Infection
4:43 p.m. Oct. 25, 2013
- BusinessWire
Gilead Sciences to Release Third Quarter 2013 Financial Results on Tuesday, October 29, 2013
5:00 p.m. Oct. 22, 2013
- BusinessWire
Stock Price Movements, Clinical Study Results, and New Appointments - Research Report on Pfizer, Gilead Sciences, Amgen, Celgene, and Insys Therapeutics
8:00 a.m. Oct. 22, 2013
- PR Newswire
Innovative Biotechs Making Strides In Healthcare Sector: Alliqua, MiMedx, Organovo, Anacor Pharmaceuticals, Pfizer
9:05 a.m. Oct. 21, 2013
- PR Newswire
Insider Trading Tips for Google, Rite Aid, American Express, Advanced Micro Devices, J.C. Penney, and Ariad Pharmaceuticals
8:55 a.m. Oct. 21, 2013
- PR Newswire
Gilead's Single Tablet HIV Regimen Stribild(R) Demonstrates Durable Viral Suppression Through Three Years of Therapy
3:10 a.m. Oct. 16, 2013
- BusinessWire
GlobeImmune Announces Milestone Payment for Initiation of Phase 2 Clinical Trial for GS-4774 (Formerly GI-13020) in Patients with Chronic Hepatitis B Virus Infection
7:00 a.m. Oct. 15, 2013
- Thomson Reuters ONE
(0)
(0)
